Comparing Legal, Economic, and Legislative Approaches to Nutritional Labeling of Fast Food Items
by Michael A. McCann, LL.M. Candidate at Harvard Law School and House Judiciary Committee Fellow to U.S. Representative Martin T. Meehan (D-MA)

Obesity in the United States: An Overview
by Ioana G. Carabin, M.D., President and Medical Director of Women's Health Sciences Institute, Inc., a not-for-profit organization in Vero Beach, FL and
George A. Burdock, Ph.D., Principal of Burdock Group, Washington, D.C.

Obesity in America: Litigation Is Not Part of the Solution
by Jane F. Thorpe, Partner in the Products Liability practice group at Alston & Bird, LLP, Atlanta, GA and
David Venderbush, Of Counsel in the Products Liability practice group at Alston & Bird, LLP, New York, NY and
Scott A. Elder, Associate in the Products Liability practice group at Alston & Bird, LLP, Atlanta, GA

New Food Labeling Requirements on the Horizon: The Food Allergen Labeling and Consumer Protection Act of 2004
by Ricardo Carvajal, Associate Chief Counsel, Food and Drug Division, Office of General Counsel (OGC), Department of Health and Humans Services (DHHS)

The United States Must Declare War Against Obesity
by Dong Geng, M.S., Director of the Policies and Regulations Division, Food and Drug Administration of Zhejiang Province, China

Canada and the United States: Crossborder Issues Relevant to the Dietary Supplements Industry
by Michael Penny, Partner in the Litigation Department of the Toronto office of Torys LLP and
Conan McIntyre, Associate in the Toronto office of Torys LLP

When Novel Food Turns Conventional—Bavarian Administrative Court Challenges the European View on Stevia
by Ina Gerstberger, Attorney (Rechtsanwältin) specializing in pharmaceutical and food law with the law firm Ashurst, Munich, Germany

Target Product Profile: Beginning Drug Development With the End in Mind
by Jeanne M. Delasko, Label Initiatives Specialist with the Study Endpoints and Label Development Team in the Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD and
David M. Cocchetto, Vice President, Antiviral/Antibacterial, Regulatory Affairs, with GlaxoSmithKline, Research Triangle Park, NC and
Laurie B. Burke, Director, Study Endpoints and Label Development Team in the Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD

Bringing More Drugs and Biologics to Market Sooner: FDA Clarifies Meaning of "Available Therapy"
by Patricia J. Kaeding, Attorney in the law firm of Godfrey & Kahn, S.C., Madison, Wisconsin. She worked as an attorney in FDA's Office of the Chief Counsel from 1993-2003.

Expanding FDA's Authority to Protect the Food Supply: Administrative Detention
by Frances K. Wu, Principal in the law firm of Hyman, Phelps & McNamara, P.C., Washington, D.C.

Canadian Competition Law and Internet Pharmacies
by Benjamin Little, Associate in the law firm of Blake, Cassels & Graydon LLP, Toronto, Ontario, Canada and
Jeffrey Shafer, law student in the law firm of Blake, Cassels & Graydon LLP, Toronto, Ontario, Canada

Compliance Q&A Corner
by John T. Bentivoglio, Partner with the law firm of King & Spalding LLP, Washington, D.C. and
Naoko Fujii, Senior Director of Health Care Compliance for Scios, Inc., Fremont, CA

History Corner
Looking Back and Forward: The Upcoming Centennial of the 1906 Pure Food and Drugs Act
by Suzanne White Junod, Ph.D., Historian with the Food and Drug Administration, Rockville, MD

Enforcement Corner
Corporate Deferred Prosecution: Showing Some Concern for the Shareholders
by Steven M. Kowal, Chair of the White Collar Criminal Defense Group at the law firm of Bell, Boyd & Lloyd LLC, Chicago, IL

Global Corner
Regulation by NonRegulators
by Matthew R. Weinberg, Chief Executive Officer, THE WEINBERG GROUP, Washington, D.C.